Table 3.
Cox proportional hazard analyzes for OS after CBZ treatment
| Univariate | Multivariate | Multivariate (Stepwise) | ||||
|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P | Odds ratio (95% CI) | P | Odds ratio (95% CI) | P | |
| Age (y) > 70 | 1.14 (0.64–2.04) | 0.654 | ||||
| PS ≥ 1 | 3.14 (1.63–6.04) | 0.001* | 1.43 (0.55–3.73) | 0.461 | ||
| GS ≥ 9 | 1.07 (0.58–2.00) | 0.827 | ||||
| PSA (ng/ml) > 100 | 2.55 (1.41–4.58) | 0.002* | 2.35 (1.07–5.18) | 0.034* | 2.84 (1.33–6.03) | 0.007* |
| Hb (g/dl) < 12 | 1.95 (1.03–3.72) | 0.042* | 2.03 (0.80–5.15) | 0.136 | 2.50 (1.09–5.73) | 0.030* |
| LDH (U/L) > 300 | 2.03 (1.10–3.74) | 0.023* | 1.08 (0.45–2.60) | 0.864 | ||
| ALP (U/L) > 350 | 1.98 (1.07–3.67) | 0.030* | 1.98 (0.83–4.69) | 0.122 | ||
| Bone meta at diagnosis | 1.00 (0.55–1.81) | 0.998 | ||||
| Time to CRPC (y) < 1 | 1.42 (0.79–2.54) | 0.238 | ||||
| DTX cycle< 10 | 1.81 (0.95–3.43) | 0.071 | ||||
| ABI or ENZA | 1.66 (0.76–3.60) | 0.201 | ||||
| Low Initial CBZ dose | 2.22 (1.11–4.43) | 0.023* | 2.15 (0.48–9.76) | 0.32 | 2.81 (1.11–7.13) | 0.030* |
| RDI 60% or lower | 2.76 (1.24–6.17) | 0.013* | 1.26 (0.36–4.34) | 0.717 | ||
PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
RDI:relative dose intensity, *P < 0.05